Urgent.News

What's breaking now, across thousands of outlets.

Business

Lupin to bet big on biosimilar sales in mid term, ramp capacity expansion

The company plans to soon start the funding process for its oncology spin-off, Kaveri Therapeutics, which houses two specialised oncology programmes

Lupin to bet big on biosimilar sales in mid term, ramp capacity expansion

We haven't written up this one. Business Standard IN has the full story — the link below goes straight to it.

Read the original at business-standard.com →

More in Business

More from Sunday 13 September →